Tag: UroGen Pharma Ltd. (NASDAQ:URGN)

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -14.59% since the start of this calendar year. Looking

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -13.00% since the start of this calendar year. Looking